Role of CA 19-9/CRP Ratio as A Predictor for Malignancy in Obstructed Jaundice Patient
CA 19-9/CRP Ratio for Malignancy in Obstructed Jaundice Patient
DOI:
https://doi.org/10.54393/pjhs.v5i12.2123Keywords:
Diagnostic Accuracy, Cancer Antigen 19-9, C-Reactive Protein Ratio, MalignancyAbstract
The cancer-antigen-19-9 tumor marker, increases during biliary and pancreatic malignancy. Objectives: To determine diagnostic accuracy and role of cancer-antigen-19-9 and C-reactive-protein ratio as a predictor for malignancy in obstructive jaundice patients taking a Computed Tomography scan as the gold standard. Methods: A total of 158 patients were admitted with obstructive jaundice in Al-Tibri Hospital. Cancer-antigen-19-9 was adjusted by dividing it with the C-reactive-protein value. Malignancy was considered based on computed tomography scan findings. Specificity, sensitivity, negative predictive value, positive predictive value, and diagnostic accuracy of cancer antigen-19-9 to C-reactive protein ratio were calculated. Results: There were 57.6% male and 42.4% female patients. The mean cancer antigen-19-9 and C-reactive-protein ratio was 51.39 ± 69.40 U/ml. The significant p-values (<0.001) confirm meaningful differences in CA19-9/CRP ratios between benign and malignant cases, but low sensitivity (63.2%) and negative predictive value (46.8%) limit its clinical utility as a standalone tool. A total of 50% of patients were diagnosed as benign and 50% as malignant by cancer antigen-19-9 and C-reactive-protein ratio. However, 27.8% of patients were diagnosed as benign and 72.2% as malignant by computed tomography scan. Sensitivity, Specificity, positive predictive value, negative predictive value and accuracy were 63.2%, 84.1%, 91.1%, 46.8%, and 68.98% respectively. Conclusions: It was concluded that the cancer-antigen-19-9/CRP ratio while exhibiting moderate overall diagnostic accuracy (68.98%), provides significant diagnostic specificity (84.1%) and positive predictive value (91.1%). These characteristics make it a valuable supplemental tool for confirming malignancy in obstructive jaundice patients, particularly when used alongside other diagnostic modalities.
References
Lee T, Teng TZ, Shelat VG. Carbohydrate Antigen 19-9—Tumor Marker: Past, Present, And Future. World Journal of Gastrointestinal Surgery. 2020 Dec; 12(12): 468. doi: 10.4240/wjgs.v12.i12.468. DOI: https://doi.org/10.4240/wjgs.v12.i12.468
Mittal D, Singh J, Kaur M, Kumar A, Kaur A. To Estimate the Levels of Ca19-9 and Its Significance in the Diagnosis and Treatment of Pancreatic Biliary and Gastrointestinal Malignancies. Asian Journal of Pharmaceutical and Clinical Research. 2022; 15(5): 125-7. doi: 10.22159/ajpcr.2022.v15i5.44365. DOI: https://doi.org/10.22159/ajpcr.2022.v15i5.44365
Ghallab M, Abosheaishaa H, Gupta I, Abdelmoteleb S, Stern R. A Case of Choledocholithiasis and Obstructive Jaundice with A Very High Serum Carbohydrate Antigen 19-9 (CA 19-9) Level: A Case Report and Review of Literature. Cureus. 2022 Dec; 14(12). doi: 10.7759/cureus.32447.
Zhao B, Cheng Q, Cao H, Zhou X, Li T, Dong L et al. Dynamic Change of Serum CA19–9 Levels in Benign and Malignant Patients with Obstructive Jaundice After Biliary Drainage and New Correction Formulas. BioMed Central Cancer. 2021 May; 21(1): 517. doi: 10.1186/s12885-021-08204-w. DOI: https://doi.org/10.1186/s12885-021-08204-w
Utsumi M, Inagaki M, Kitada K, Tokunaga N, Kondo M, Yunoki K et al. Preoperative C-Reactive Protein-To-Albumin Ratio as a Prognostic Factor in Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Medicine. 2023 Jun; 102(22): e33656. doi: 10.1097/MD.0000000000033656. DOI: https://doi.org/10.1097/MD.0000000000033656
Ghallab M, Abosheaishaa H, Gupta I, Abdelmoteleb S, Stern R. A Case of Choledocholithiasis and Obstructive Jaundice with A Very High Serum Carbohydrate Antigen 19-9 (Ca 19-9) Level: A Case Report and Review of Literature. Cureus. 2022 Dec; 14(12). doi: 10.7759/cureus.32447. DOI: https://doi.org/10.7759/cureus.32447
Giron F and Alcantar D. Looks Can Be Deceiving: A Case Report On the Clinical Value of CA 19-9 in Obstructive Jaundice. Cureus. 2020 Jan; 12(1). doi: 10.7759/cureus.6637. DOI: https://doi.org/10.7759/cureus.6637
Shah M, Gonzalez F, Chernyavsky S. S1650 Severely Elevated CA19-9: Benign or Malignant? Official Journal of the American College of Gastroenterology. 2021 Oct; 116: S739-40. doi: 10.14309/01.ajg.0000780132.29425.af. DOI: https://doi.org/10.14309/01.ajg.0000780132.29425.af
La Greca G, Sofia M, Lombardo R, Latteri S, Ricotta A, Puleo S et al. Adjusting CA19-9 Values to Predict Malignancy in Obstructive Jaundice: Influence of Bilirubin and C-Reactive Protein. World Journal of Gastroenterology. 2012 Aug; 18(31): 4150. doi: 10.3748/wjg.v18.i31.4150. DOI: https://doi.org/10.3748/wjg.v18.i31.4150
Kim HS, Han Y, Kang JS, Kang YH, Lee M, Sohn HJ et al. Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 As Preoperative Diagnostic Biomarkers of Extrahepatic Bile Duct Cancer. British Journal of Surgery Open. 2021 Nov; 5(6): zrab127. doi: 10.1093/bjsopen/zrab127. DOI: https://doi.org/10.1093/bjsopen/zrab127
Zhou X. Meta-Analysis of the Diagnostic Performance of Serum Carbohydrate Antigen 19-9 for diagnosing Gallbladder Cancer. The International Journal of Biological Markers. 2022 Mar; 37(1): 81-9. doi: 10.1177/17246008211068866. DOI: https://doi.org/10.1177/17246008211068866
Lyu SC, Wang J, Huang M, Wang HX, Zhou L, He Q et al. CA19-9 Level to Serum γ-Glutamyl-transferase as a Potential Prognostic Biomarker in Patients with Pancreatic Head Carcinoma. Cancer Management and Research. 2021 Jun: 4887-98. doi: 10.2147/CMAR.S313517. DOI: https://doi.org/10.2147/CMAR.S313517
Ghosh S, Baruah M, Yadav AK, Das AK. Role of CA 19-9 and its Ratio with CRP and Total Bilirubin in Differentiating Malignant from Benign Obstructive Jaundice. Journal of Clinical and Diagnostic Research. 2019 Jan; 13(1). doi: 10.7860/JCDR/2019/38019.12477. DOI: https://doi.org/10.7860/JCDR/2019/38019.12477
Azam MG, Chowdhury AA, Sajjad SM, Datta IK, Rahman MA, Rowshon AH. Diagnostic Role of CA19-9, CA19-9/CRP Ratio and CA19-9/Total Bilirubin Ratio in Differentiating Benign and Malignant Obstructive Jaundice. Bangladesh Journal of Medicine. 2023 May; 35(2): 165-6. doi: 10.3329/bjm.v35i20.73261. DOI: https://doi.org/10.3329/bjm.v35i20.73261
Boyd LN, Ali M, Leeflang MM, Treglia G, de Vries R, Le Large TY et al. Diagnostic Accuracy and Added Value of Blood-Based Protein Biomarkers for Pancreatic Cancer: A Meta-Analysis of Aggregate and Individual Participant Data. E Clinical Medicine. 2023 Jan; 55: 101747. doi: 10.1016/j.eclinm.2022.101747. DOI: https://doi.org/10.1016/j.eclinm.2022.101747
Liu W, Liu Q, Wang W, Wang P, Chen J, Hong T et al. Differential diagnostic roles of the Serum CA19-9, Total Bilirubin (TBIL) and the Ratio of CA19-9 To TBIL for Benign and Malignant. Journal of Cancer. 2018; 9(10): 1804. doi: 10.7150/jca.25093. DOI: https://doi.org/10.7150/jca.25093
Zhang W, Wang Y, Dong X, Yang B, Zhou H, Chen L et al. Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma. Bio-Science Trends. 2021 Dec; 15(6): 397-405. doi: 10.5582/bst.2021.01517. DOI: https://doi.org/10.5582/bst.2021.01517
Wu Z, Zhao P, Wang Z, Huang X, Wu C, Li M et al. Adjusting CA19-9 Values with Clinical Stage and Bilirubin to Better Predict Survival of Respectable Pancreatic Cancer Patients: 5-Year-Follow-Up of A Single Center. Frontiers in Oncology. 2022 Jul; 12: 966256. doi: 10.3389/fonc.2022.966256. DOI: https://doi.org/10.3389/fonc.2022.966256
Sayed MM, Elshafie AI, Lotfy M, Abdelhakam SM, Rushdy M. Clinical Significance of Serum CA 19-9, CA 19-9/CRP Ratio and CA19-9/Total Bilirubin Ratio in Differentiation Between Malignant and Benign Obstructive Jaundice. European Academic Research. 2017; 12: 10271-91.
Huang X, Lu Z, Zhang K, Wang G, Cai B, Wu P et al. Prognostic Impact of the Ratio of Preoperative CA19-9 to Liver Enzyme Levels in Pancreatic Cancer Patients with Jaundice (Predictability of Combined CA19-9/AST and CA19-9/γ-GGT for Jaundiced PDAC Patients). Pancreatology. 2021 Sep; 21(6): 1092-101. doi: 10.1016/j.pan.2021.05.300. DOI: https://doi.org/10.1016/j.pan.2021.05.300
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
